ArticleScientific reports2025
Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Random Association of Ultraconserved Genomic Elements (UCE) with Human Genes.International journal of molecular sciences · 2026Article
- Unpacking the Tumor Protein D52-like Family: Roles in Intracellular Trafficking and Cancer Progression.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Prostate cancer (PCa) ranks among the most prevalent malignant tumors worldwide. The pivotal role of competitive endogenous RNA (ceRNA) regulatory networks in numerous cancer types has been underscored. However, the specific characteristics of the ceRNA network in PCa remained unknown. This study aims to elucidate the ceRNA regulatory network associated with phosphatase and tensin homolog (PTEN) and to identify potential prognostic markers for PCa. The Cancer Genome Atlas (TCGA) database was employed to extract the expression patterns of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs). LINC01122-hsa-miR-34c-5p/hsa-miR-449a-TPD52 ceRNA network regarding the prognosis of PCa was explored via bioinformatics analysis. Through correlation analysis, we investigated the LINC01122/TPD52 axis within the ceRNA network, identifying it as a significant clinical prognostic marker for PCa. Subsequent analyses indicated that hypomethylation was responsible for the abnormal upregulation of the LINC01122/TPD52 axis. Furthermore, immune infiltration analysis revealed the impact of the LINC01122/TPD52 axis on the tumor immune microenvironment and the progression of PCa. Finally, a nomogram was constructed to forecast the 1-year, 3-year, and 5-year survival probabilities of PCa patients. In summary, our study demonstrates the significant role of the ceRNA-based LINC01122/TPD52 axis in the progression of PCa and its correlation with prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.